Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2002

View Archived Issues

A crossover study provides evidence of the analgesic properties of reboxetine

NC-1900 improves place learning deficits in rats after transient forebrain ischemia

Fumagillin is effective against intestinal microsporidiosis in immunocompromised patients

New PDE4 inhibitors in early development at Merck KGaA

New ERbeta modulators and their use in Alzheimer's, anxiety, osteoporosis, etc.

Novel MCH antagonists covered by Schering-Plough patent

Ishihara Sangyo describes new inhibitors of Th1 and/or Th2 cytokine production

New ACAT inhibitors prepared and tested by Pola researchers

Alkermes and Reliant call off merger

Ovation acquires Tranxene and Desoxyn from Abbott

Aphton seeks E.U. clearance for G17DT trial in GERD

Yamanouchi discontinues YM-175

MT-100 provides significant pain relief in difficult-to-treat migraine patients

Antisoma completes enrollment in phase I TheraFab trial

Xcytrin to enter new phase III trial in NSCLC patients

Ortho Tri-Cyclen Lo receives FDA approval

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...